Monoclonal antibody · Antagonist of CD6 · developed by Biocon
Phase 3Most advanced trial (none active)
2Registered trials
What is Itolizumab?
Itolizumab is a humanized IgG1 monoclonal antibody that binds CD6, a co-stimulatory molecule on T cells involved in their adhesion and maturation. By blocking CD6-mediated activation pathways, it downregulates T-cell activation and reduces pro-inflammatory cytokine synthesis. It is studied in asthma and graft-versus-host disease.
Summary written with AI from the sources listed at the end of this page.
At a glance
Also known as
EQ-001, BMAB-600
Drug type
Monoclonal antibody
Targets
CD6
Mechanism
Antagonist of CD6
Pathways
T-cell activation and differentiation, pro-inflammatory cytokine synthesis
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.